Antiviral resistance in Egyptian hepatitis B patients
Part of Digestive system, Infections clinical trials.
This study looks at why some people with chronic hepatitis B develop resistance to antiviral medications. It may help doctors choose better treatments for patients taking tenofovir, entecavir, or lamivudine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have chronic hepatitis B (positive HBsAg for more than 6 months).
- You are currently taking one of these medications: tenofovir (TDF), entecavir (ETV), or lamivudine.
- You may or may not have cirrhosis (liver scarring).
- You are Egyptian (this study is based in Egypt).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether hepatitis B virus becomes resistant to a drug called entecavir in people in Turkey. It may help doctors understand why some people's treatment stops working.
This trial studies what happens after stopping long-term hepatitis B antiviral medicine in people whose virus has stayed controlled. It also follows patients over time to see how well they remain stable and safe after stopping.
This study looks at how hepatitis B virus changes in your body, including mutations and drug resistance, using your blood or liver tissue samples. Understanding these changes could help improve treatment for hepatitis B.
This study looks at how to best use existing hepatitis B “nucleotide-analog” tablets in everyday care. It may help tailor when to start, and whether to continue or adjust treatment, based on your test results.
This study looks at the genes of people with chronic hepatitis B (HBV) to find why some people's immune cells (B cells and NK cells) stop working properly. The goal is to discover new ways to treat the disease.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
Hear when a new Chronic Hepatitis B - Antiviral Drug Resistance - Hepatitis B Virus (HBV) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.